USD
GBP 
CNY 
EUR 
INR 
JPY 
MYR 
ZAR 
KRW 
THB 
Launch of Several Pipeline Oral Products Could Diminish the Market for Injectable Therapies
This market insight provides data for the global multiple sclerosis (MS) market. The analysis looks at MS pharmaceutical pipeline drugs that are currently in the market as well as any drugs that are in Phase III trials and pose a potential threat to competitors. It offers a competitive analysis of these drugs and the forecasted outcome and impact of each of these drugs. Injectable drugs dominate MS drugs currently in the market, but the launch of numerous oral pipeline products can shift this market in favor of oral drugs. The MS market is segmented into relapsing, remitting, secondary progressive, primary progressive, and progressive relapsing MS drugs.
Key Findings
Recent Market Developments
Recent Market Developments (continued)
Defining Healthcare Trends in the Future
Defining Healthcare Trends in the Future (continued)
Companies to Watch
Methodology and Scope
Introduction
Market Overview—Segmentation
Market Overview—Segmentation (continued)
Market Overview—Segmentation (continued)
Prevalence of MS in Major Market
Prevalence of MS in Major Market (continued)
Physician Guidelines to MS Therapy
Competitive Landscape—Count of Marketed and Pipeline Products
MS Therapeutics Competitive Landscape
Marketed Product Analysis
Marketed Product Analysis (continued)
Pipeline Analysis—Products in Clinical Development
Pipeline Analysis—Products in Clinical Development (continued)
Pipeline Analysis—Products in Clinical Development (continued)
Pipeline Analysis—Products in Clinical Development (continued)
Pipeline Analysis—Products in Clinical Development (continued)
Pipeline Analysis—Products in Clinical Development (continued)
Pipeline Analysis—Products in Clinical Development (continued)
Product Launch Timeline
Patent Expiration Timeline
Marketed Products Clinical Program—AUBAGIO (Teriflunomide)
Marketed Products Clinical Program—Plegridy
Marketed Products Clinical Program—Tysabri
Marketed Products Clinical Program—Tecfidera
Pipeline Products Clinical Program—Ocrelizumab, Ofatumumab
Pipeline Products Clinical Program—Lemtrada
Product Dashboard—Copaxone
Product Dashboard—Avonex (interferon beta-1a)
Product Dashboard—Betaseron/Extavia (interferon beta-1b)
Product Dashboard—Rebif (interferon beta-1a)
Product Dashboard—Tysabri (natalizumab)
Product Dashboard—Gilenya
Product Dashboard—Tecfidera (oral Glatiramer Fumarate)
Product Dashboard—Aubagio (Teriflunomide)
Product Dashboard—Plegridy (BIIB017) (pegylated interferon beta-1a)
Product Dashboard—Lemtrada/Campath 1G (Alemtuzumab)
Product Dashboard—Laquinimod
Product Dashboard—Zenapax (daclizumab)
Product Dashboard—Ocrelizumab
Product Dashboard—AB1010 (Masitinib)
Product Dashboard—Ofatumumab
Conclusions and Recommendations
Legal Disclaimer
The Frost & Sullivan Story
Value Proposition
Global Perspective
Industry Convergence
360º Research Perspective
Implementation Excellence
Our Blue Ocean Strategy
Speak directly with our analytics experts for tailored recommendations.
Recent related industry research
17 Sep 2026 | Asia Pacific | Frost Radar
Frost Radar™: Facility Management in Malaysia, 2026
Malaysia's facility management (FM) market is transitioning from labor-intensive, compliance-driven service delivery to technology-enabled, outcome-oriented, and sustainability-integrated operating models. Competitive differentiation increasingly depends on providers’ ability to combine integrated F...
17 Sep 2026 | Global | Market Research
Growth Opportunities in the Western Europe Consumer eSIM Market, 2026–2029
The consumer eSIM market in Western Europe is growing steadily, supported by the rising availability of eSIM-capable devices, particularly smartphones, and expanding travel-related use cases. However, commercialization has yet to translate into mass adoption. Despite Apple’s global launch of an eSIM...
17 Sep 2026 | Asia Pacific | Frost Radar
Frost Radar™: ASEAN Warehouse Automation System Providers, 2026
Warehouse automation has moved from a discretionary capital project to a core operating capability. ASEAN operators are redesigning fulfillment networks around smaller orders, shorter delivery windows, broader stock keeping unit (SKU) ranges, and sharper demand volatility. Manual operations remain v...
16 Sep 2026 | North America | Customer Research
US Automotive Technicians’ Choice Survey, 2025
The 2025 US Automotive Technicians’ Choice study is an insightful voice-of-customer survey that highlights the tool preferences of automotive aftermarket service technicians. The survey of 400 automotive technicians across the United States used a combination of computer-assisted telephone and compu...
16 Sep 2026 | Global | Market Research
Apple Performance Tracker, Q1 2026
This Frost & Sullivan tracker provides metrics on Apple's quarterly performance (for both unit sales and revenues) for iPads, iPhones, Macs, and other products, such as iPods, Apple TVs, Beats Electronics, and Apple-branded and third-party accessories. It includes historical quarterly data for all t...
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
| Deliverable Type | Market Research |
|---|---|
| No Index | No |
| Podcast | No |
| Author | Aish Vivekanadan |
| WIP Number | NEC3-01-00-00-00 |
| Is Prebook | No |